Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus

Journal of Rheumatology

Volumn 39, Issue 4, 2012, Pages 735-742

  Harrison, Mark J ^a   Ahmad, Yasmeen ^b   Haque, Sahena ^c   Dale, Nicola ^a   Teh, Lee Suan ^d   Snowden, Neil ^e   Ho, Pauline ^c   Gorodkin, Rachel ^c   Bruce, Ian N ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Llandudno LL30 1LB   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d ROYAL BLACKBURN HOSPITAL   (United Kingdom)

^e NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Health related quality of life; Health state utility; SF 6D; Systemic lupus erythematosus; Validity

Indexed keywords

ADULT; ARTICLE; BODY IMAGE; CAROTID ATHEROSCLEROSIS; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CLINICAL FEATURE; CONSTRUCT VALIDITY; CONTROLLED STUDY; COST UTILITY ANALYSIS; CRITERION RELATED VALIDITY; DEPRESSION; DISCRIMINANT VALIDITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FATIGUE; FEMALE; HUMAN; INSTRUMENT VALIDATION; INTIMACY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 6D; SMOKING HABIT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; QUESTIONNAIRES;

EID: 84859471402     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110648     Document Type: Article

References (39)

1. Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008;35:2152-8.
2. McElhone K, Abbott J, The LS. A review of health related quality of life in systemic lupus erythematosus. Lupus 2006;15:633-43. (Pubitemid 44682824)
3. Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005;32:1706-8. (Pubitemid 41324807)
4. Kuriya B, Gladman DD, Ibanez D, Urowitz MB. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008;59:181-5. (Pubitemid 351272952)
5. Bruce IN. Re-evaluation of biologic therapies in systemic lupus erythematosus. Curr Opin Rheumatol 2010;22:273-7.
6. US Food and Drug Administration. FDA approves Benlysta to treat lupus. [Internet. Accessed December 3, 2011.] Available from: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm
7. Bansback N, Harrison M, Brazier J, Davies L, Kopec J, Marra C, et al. Health state utility values: A description of their development and application for rheumatic diseases. Arthritis Rheum 2008;59:1018-26. (Pubitemid 351991000)
8. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. York: The University of York: Centre for Health Economics; 1999.
9. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108. (Pubitemid 127453463)
10. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): Concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54.
11. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92. (Pubitemid 34143147)
12. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004;42:851-9. (Pubitemid 39456916)
13. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007;57:972-9. (Pubitemid 47237322)
14. Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP. The validity and responsiveness of generic utility measures in rheumatoid arthritis: A review. J Rheumatol 2008;35:592-602. (Pubitemid 351500053)
15. Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36. Its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997;24:1608-14. (Pubitemid 27320706)
16. Thumboo J, Fong KY, Ng TP, Leong KH, Feng PH, Thio ST, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1999;26:97-102. (Pubitemid 29051403)
17. Schiffenbauer J, Simon LS. Randomized controlled trials in systemic lupus erythematosus: What has been done and what do we need to do? Lupus 2004;13:398-405. (Pubitemid 38788503)
18. Yazdany J, Yelin EH, Panopalis P, Trupin L, Julian L, Katz PP. Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort. Arthritis Care Res 2008;59:136-43. (Pubitemid 351171889)
19. Fernandez M, Alarcon GS, McGwin G Jr, Sanchez ML, Apte M, Vila LM, et al. Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII. Results from a multiethnic US cohort. Arthritis Rheum 2007;57:986-92. (Pubitemid 47237324)
20. Aggarwal R, Wilke CT, Pickard AS, Vats V, Mikolaitis R, Fogg L, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol 2009;36:1209-16.
21. Sanchez ML, McGwin G Jr, Duran S, Fernandez M, Reveille JD, Vila LM, et al. Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): Use of the SF-6D. Clin Exp Rheumatol 2009;27:67-71.
22. Ahmad Y, Bruce IN. Subclinical atherosclerosis in systemic lupus erythematosus. J Rheumatol 2004;31:841-3. (Pubitemid 38585803)
23. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
24. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91. (Pubitemid 34118775)
25. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13. (Pubitemid 27199995)
26. Barta Z, Harrison MJ, Wangrangsimakul T, Shelmerdine J, The LS, Pattrick M, et al. Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus. Lupus 2010;19:231-8.
27. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
28. Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, The LS, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): The relative contribution of classic risk factors and the lupus phenotype. Rheumatology 2007;46:983-8. (Pubitemid 47062508)
29. Li RL, Duncan BB, Metcalf PA, Crouse JR, Sharrett AR, Tyroler HA, et al. B mode-detected carotid artery plaque in a general population. Stroke 1994;25:2377-83. (Pubitemid 24359305)
30. Cohen J. Statistical power analysis for the behavioural sciences. Mahwah, New Jersey: Lawrence Earlbaum; 1977.
31. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ5D) and disease specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82. (Pubitemid 40126441)
32. Veenhof C, Bijlsma JWJ, van den Ende CHM, van Dijk GM, Pisters MF, Dekker J. Psychometric evaluation of osteoarthritis questionnaires: A systematic review of the literature. Arthritis Care Res 2006;55:480-92. (Pubitemid 43890904)
33. McHorney CA, Tarlov A. Individual patient monitoring in clinical practice: Are available health status measures adequate? Qual Life Res 1995;4:293-307.
34. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997;36:786-93.
35. OMERACT. Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Proceedings. Maastricht, The Netherlands, April 29-May 3, 1992. J Rheumatol 1993;20:527-91.
36. Gladman DD, Urowitz MB, Ong A, Gough J, MacKinnon A. Lack of correlation among the 3 outcomes describing SLE: Disease activity, damage and quality of life. Clin Exp Rheumatol 1996;14:305-8. (Pubitemid 26290872)
37. Jolly M, Utset TO. Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus 2004;13:924-6. (Pubitemid 39664951)
38. The EuroQol Group. EuroQol - A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
39. Roman MJ, Shanker B, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406. (Pubitemid 37542988)